A retrospective real-world study assessing the efficacy of receptor tyrosine kinase and immune checkpoint inhibitors and insights to potential combinatorial treatment strategies in cholangiocarcinomas
Latest Information Update: 28 May 2021
At a glance
- Drugs Camrelizumab (Primary) ; Catequentinib (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Regorafenib (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary) ; Sorafenib (Primary) ; Toripalimab (Primary)
- Indications Cholangiocarcinoma
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 28 May 2021 New trial record
- 21 May 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research